ArticleFrontiers in cardiovascular medicine2026
Exploring the mechanism of Yi Qi Huo Xue compound prescription in treating chronic heart failure based on integrated network pharmacology and transcriptomics.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From Single Genes to Systemic Networks: Transcriptomic Insights into Traditional Chinese Medicine for Heart Failure.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic heart failure (CHF) represents a major global health burden characterized by complex pathologies. The Yi Qi Huo Xue compound prescription (YQHXCP) has demonstrated significant clinical efficacy in alleviating heart failure symptoms; however, its precise molecular mechanisms remain obscure. Objective: This study aims to elucidate the core targets and biological pathways of YQHXCP in treating CHF through an integrated approach combining network pharmacology with transcriptomic validation. Methods: A rat model of heart failure was established, and transcriptomic data were acquired via RNA sequencing. Concurrently, putative targets of YQHXCP were retrieved from the TCMSP and SwissTargetPrediction databases. Key targets were identified by intersecting differentially expressed genes (DEGs) from the animal model with predicted drug targets. Subsequently, functional enrichment analysis, gene-gene interaction (GGI) network construction, and molecular docking were employed to decipher the underlying mechanisms, followed by Results: Three pivotal target genes were identified: Top2a, Cdk1, and E2f2. Enrichment analysis revealed that YQHXCP primarily modulates mitochondrial protein complexes, ribosomal subunit assembly, and cell cycle checkpoints. Molecular docking demonstrated strong binding affinity between the active ingredient quercetin and both Cdk1 and E2f2 proteins. RT-qPCR confirmed that YQHXCP significantly reversed the downregulation of Cdk1 and E2f2 expression in the myocardial tissue of CHF rats. Conclusion: YQHXCP may exert its anti-CHF effects by targeting Cdk1 and E2f2 to regulate mitochondrial function and cell cycle homeostasis. These findings provide novel insights into the multi-target therapeutic mechanisms of traditional Chinese medicine formulations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.